What is the recommended dosing when converting a patient from oxycodone to tramadol (tramadol hydrochloride)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Oxycodone to Tramadol Conversion Dosing

When converting from oxycodone to tramadol, use a conversion ratio of approximately 1:7.5, with a recommended starting dose of tramadol 50-100 mg every 4-6 hours, not to exceed 400 mg daily. 1, 2

Conversion Calculation

  • Based on morphine milligram equivalent (MME) conversion factors, tramadol has a potency of 0.2 compared to morphine, while oxycodone has a potency of 1.5 compared to morphine 1
  • This creates an approximate conversion ratio of 7.5:1 (tramadol:oxycodone) 1
  • Practical conversion examples:
    • 25-30 mg daily oxycodone ≈ 200 mg daily tramadol 1
    • 40 mg daily oxycodone ≈ 300 mg daily tramadol 1
    • 50-55 mg daily oxycodone ≈ 400 mg daily tramadol (maximum recommended dose) 1

Dosing Strategy

  • Start tramadol at 50 mg once or twice daily and increase gradually as needed to a maximum of 400 mg/day 3, 2
  • For patients requiring rapid onset of analgesic effect, tramadol 50-100 mg can be administered every 4-6 hours, not exceeding 400 mg daily 2
  • For patients not requiring rapid onset, initiate with a titration regimen to improve tolerability:
    • Start at lower doses and increase by 50 mg every 3 days as tolerated to reach 200 mg/day 2
    • After titration, administer 50-100 mg every 4-6 hours as needed 2

Special Populations

  • For patients with creatinine clearance <30 mL/min: increase dosing interval to 12 hours with maximum daily dose of 200 mg 2
  • For patients with cirrhosis: 50 mg every 12 hours 2
  • For elderly patients (>65 years): start at the low end of the dosing range 2
  • For elderly patients (>75 years): total dose should not exceed 300 mg/day 2

Important Considerations

  • Tramadol is a weak μ-opioid agonist that also inhibits reuptake of serotonin and norepinephrine 3, 4
  • Tramadol has a lower risk of abuse compared to oxycodone and other strong opioids 3, 4
  • Tramadol is considered a second-line medication for neuropathic pain but may be used as first-line in certain circumstances (acute neuropathic pain, cancer pain, episodic severe pain) 3
  • The analgesic effect of tramadol begins within one hour and peaks in approximately two hours 5

Adverse Effects and Monitoring

  • Common adverse effects include dizziness, nausea, vomiting, dry mouth, constipation, and sedation 5
  • Tramadol lowers the seizure threshold and can interact with SSRIs and SNRIs to cause serotonin syndrome 3
  • Adverse effects are dose-dependent, particularly nausea, so starting with lower doses during the first days of treatment improves tolerability 4, 6
  • Monitor for signs of respiratory depression, though this is generally less severe than with strong opioids 4

Pharmacogenetic Considerations

  • CYP2D6 genotype affects tramadol metabolism and efficacy 7
  • For CYP2D6 ultra-rapid metabolizers, consider decreasing the dose to 40% of the commonly prescribed dose or use an alternative analgesic 7
  • For CYP2D6 poor metabolizers or intermediate metabolizers with insufficient analgesia, consider an alternative analgesic not metabolized by CYP2D6 7

By following these guidelines for converting from oxycodone to tramadol, clinicians can provide effective pain management while minimizing adverse effects and considering individual patient factors.

References

Guideline

Tramadol to Oxycodone Dosing Conversion

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

[Pharmacology of tramadol].

Drugs, 1997

Research

Tramadol: a new centrally acting analgesic.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.